Pharmacology and potential physiological significance of schistosome multidrug resistance transporters

Experimental Parasitology

Volumn 132, Issue 1, 2012, Pages 2-6

  Kasinathan, Ravi S ^a   Greenberg, Robert M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ABC transporters; Drug resistance; Multidrug resistance; P glycoprotein; Schistosoma

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PRAZIQUANTEL; RNA;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ATP BINDING CASSETTE TRANSPORTER A3 GENE; ATP BINDING CASSETTE TRANSPORTER A4 GENE; ATP BINDING CASSETTE TRANSPORTER B1 GENE; ATP BINDING CASSETTE TRANSPORTER B6 GENE; ATP BINDING CASSETTE TRANSPORTER B7 GENE; ATP BINDING CASSETTE TRANSPORTER B8 GENE; ATP BINDING CASSETTE TRANSPORTER C1 GENE; ATP BINDING CASSETTE TRANSPORTER C4 GENE; ATP BINDING CASSETTE TRANSPORTER E1 GENE; ATP BINDING CASSETTE TRANSPORTER F1 GENE; ATP BINDING CASSETTE TRANSPORTER F2 GENE; ATP BINDING CASSETTE TRANSPORTER G1 GENE; ATP BINDING CASSETTE TRANSPORTER G2 GENE; ATP BINDING CASSETTE TRANSPORTER G4 GENE; ATP BINDING CASSETTE TRANSPORTER GENE; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MECHANISM; GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; HOST PARASITE INTERACTION; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS MANSONI;

ANIMALS; ANTHELMINTICS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; GENES, MDR; HUMANS; PRAZIQUANTEL; SCHISTOSOMA; TOXINS, BIOLOGICAL; XENOBIOTICS;

SCHISTOSOMA; VERMES;

EID: 80052459275     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.03.004     Document Type: Review

References (57)

1. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
2. Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmac. Ther. 1985, 29:129-156.
3. Aragon A.D., Imani R.A., Blackburn V.R., Cupit P.M., Melman S.D., Goronga T., Webb T., Loker E.S., Cunningham C. Towards an understanding of the mechanism of action of praziquantel. Mol. Biochem. Parasitol. 2009, 164:57-65.
4. Ardelli B.F., Guerriero S.B., Prichard R.K. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol. Biochem. Parasitol. 2005, 143:58-66.
5. Ardelli B.F., Guerriero S.B., Prichard R.K. Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: linkage disequilibrium and genotype diversity. Parasitology 2006, 132:375-386.
6. Bartley D.J., McAllister H., Bartley Y., Dupuy J., Menez C., Alvinerie M., Jackson F., Lespine A. P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus. Parasitology 2009, 136:1081-1088.
7. Berriman M., Haas B.J., LoVerde P.T., Wilson R.A., Dillon G.P., Cerqueira G.C., Mashiyama S.T., Al-Lazikani B., Andrade L.F., Ashton P.D., Aslett M.A., Bartholomeu D.C., Blandin G., Caffrey C.R., Coghlan A., Coulson R., Day T.A., Delcher A., DeMarco R., Djikeng A., Eyre T., Gamble J.A., Ghedin E., Gu Y., Hertz-Fowler C., Hirai H., Hirai Y., Houston R., Ivens A., Johnston D.A., Lacerda D., Macedo C.D., McVeigh P., Ning Z., Oliveira G., Overington J.P., Parkhill J., Pertea M., Pierce R.J., Protasio A.V., Quail M.A., Rajandream M.A., Rogers J., Sajid M., Salzberg S.L., Stanke M., Tivey A.R., White O., Williams D.L., Wortman J., Wu W., Zamanian M., Zerlotini A., Fraser-Liggett C.M., Barrell B.G., El-Sayed N.M. The genome of the blood fluke Schistosoma mansoni. Nature 2009, 460:352-358.
8. Blackhall W.J., Liu H.Y., Xu M., Prichard R.K., Beech R.N. Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Mol. Biochem. Parasitol. 1998, 95:193-201.
9. Blackhall W.J., Prichard R.K., Beech R.N. P-glycoprotein selection in strains of Haemonchus contortus resistant to benzimidazoles. Vet. Parasitol. 2008, 152:101-107.
10. Bosch I.B., Wang Z.X., Tao L.F., Shoemaker C.B. Two Schistosoma mansoni cDNAs encoding ATP-binding cassette (ABC) family proteins. Mol. Biochem. Parasitol. 1994, 65:351-356.
11. Caffrey C.R. Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol. 2007, 11:433-439.
12. Coley H.M. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. Methods Mol. Biol. 2010, 596:341-358.
13. Couto F.F., Coelho P.M., Araujo N., Kusel J.R., Katz N., Mattos A.C. Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel. Parasitology 2010, 137:1791-1797.
14. Day T.A., Botros S. Drug resistance in schistosomes. Parasitic Flatworms: Molecular Biology, Biochemistry, Immunology and Physiology 2006, 256-268. CAB International, Oxfordshire, UK. A. Maule, N.J. Marks (Eds.).
15. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11:1156-1166.
16. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infecti. Dis. 2008, 21:659-667.
17. Doenhoff M.J., Hagan P., Cioli D., Southgate V., Pica-Mattoccia L., Botros S., Coles G., Tchuem Tchuente L.A., Mbaye A., Engels D. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009, 1:11.
18. Doenhoff M.J., Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert. Rev. Anti. Infect. Ther. 2006, 4:199-210.
19. Fenwick A., Savioli L., Engels D., Robert Bergquist N., Todd M.H. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. 2003, 19:509-515.
20. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nature Rev. Cancer 2010, 10:147-156.
21. Gimenez-Bonafe P., Guillen Canovas A., Ambrosio S., Tortosa A., Perez-Tomas R. Drugs modulating MDR 2008, 63-99. Research Signpost, Kerala, India. N.A. Colabufo (Ed.).
22. 2+ channels targets of praziquantel action?. Int. J. Parasitol. 2005, 35:1-9.
23. Hagan P., Appleton C.C., Coles G.C., Kusel J.R., Tchuem-Tchuente L.A. Schistosomiasis control: keep taking the tablets. Trends Parasitol. 2004, 20:92-97.
24. Hayeshi R., Masimirembwa C., Mukanganyama S., Ungell A.L. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur. J. Pharm. Sci. 2006, 29:70-81.
25. Hotez P.J., Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Neglect. Trop. D 2009, 3:e485.
26. James C.E., Hudson A.L., Davey M.W. Drug resistance mechanisms in helminths: is it survival of the fittest?. Trends Parasitol. 2009, 25:328-335.
27. James C.E., Hudson A.L., Davey M.W. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol. 2009, 25:538-539.
28. Johnstone R.W., Ruefli A.A., Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem. Sci. 2000, 25:1-6.
29. Johnstone R.W., Ruefli A.A., Tainton K.M., Smyth M.J. A role for P-glycoprotein in regulating cell death. Leukemia Lymphoma 2000, 38:1-11.
30. Jones P.M., George A.M. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int. J. Parasitol. 2005, 35:555-566.
31. Kasinathan R.S., Goronga T., Messerli S.M., Webb T.R., Greenberg R.M. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J. 2010, 24:128-135.
32. Kasinathan R.S., Morgan W.M., Greenberg R.M. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol. Biochem. Parasitol. 2010, 173:25-31.
33. Kerboeuf D., Blackhall W., Kaminsky R., von Samson-Himmelstjerna G. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int. J. Antimicrob. Ag. 2003, 22:332-346.
34. King, C.H., 2010. Schistosomiasis: challenges and opportunities, Institute of Medicine, Board on Global Health, Forum on Microbial Threats. Institute of Medicine. http://iom.edu.
35. Kumkate S., Chunchob S., Janvilisri T. Expression of ATP-binding cassette multidrug transporters in the giant liver fluke Fasciola gigantica and their possible involvement in the transport of bile salts and anthelmintics. Mol. Cell. Biochem. 2008, 317:77-84.
36. Kusel J.R., Oliveira F.A., Todd M., Ronketti F., Lima S.F., Mattos A.C., Reis K.T., Coelho P.M., Thornhill J.A., Ribeiro F. The effects of drugs, ions, and poly-l-lysine on the excretory system of Schistosoma mansoni. Mem. I Oswaldo Cruz. 2006, 101(Suppl. 1):293-298.
37. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. The Oncologist 2003, 8:411-424.
38. Lespine A., Alvinerie M., Vercruysse J., Prichard R.K., Geldhof P. ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol. 2008, 24:293-298.
39. Liang X.J., Aszalos A. Multidrug transporters as drug targets. Curr. Drug Targets 2006, 7:911-921.
40. Melman S.D., Steinauer M.L., Cunningham C., Kubatko L.S., Mwangi I.N., Wynn N.B., Mutuku M.W., Karanja D.M., Colley D.G., Black C.L., Secor W.E., Mkoji G.M., Loker E.S. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Neglect. Trop. D 2009, 3:e504.
41. Messerli S.M., Kasinathan R.S., Morgan W., Spranger S., Greenberg R.M. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol. Biochem. Parasitol. 2009, 167:54-59.
42. Mizutani T., Masuda M., Nakai E., Furumiya K., Togawa H., Nakamura Y., Kawai Y., Nakahira K., Shinkai S., Takahashi K. Genuine functions of P-glycoprotein (ABCB1). Curr. Drug Metab. 2008, 9:167-174.
43. Oliveira F.A., Kusel J.R., Ribeiro F., Coelho P.M. Responses of the surface membrane and excretory system of Schistosoma mansoni to damage and to treatment with praziquantel and other biomolecules. Parasitology 2006, 132:321-330.
44. Pica-Mattoccia L., Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol. 2004, 34:527-533.
45. Redman C.A., Robertson A., Fallon P.G., Modha J., Kusel J.R., Doenhoff M.J., Martin R.J. Praziquantel: an urgent and exciting challenge. Parasitol. Today 1996, 12:14-20.
46. Sabah A.A., Fletcher C., Webbe G., Doenhoff M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 1986, 61:294-303.
47. Sangster N.C., Bannan S.C., Weiss A.S., Nulf S.C., Klein R.D., Geary T.G. Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoproteins. Exp. Parasitol. 1999, 91:250-257.
48. Sato H., Kusel J.R., Thornhill J. Functional visualization of the excretory system of adult Schistosoma mansoni by the fluorescent marker resorufin. Parasitology 2002, 125:527-535.
49. Sato H., Kusel J.R., Thornhill J. Excretion of fluorescent substrates of mammalian multidrug resistance-associated protein (MRP) in the Schistosoma mansoni excretory system. Parasitology 2004, 128:43-52.
50. Shukla S., Wu C.P., Ambudkar S.V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert. Opin. Drug Metab. Toxicol. 2008, 4:205-223.
51. Toure S., Zhang Y., Bosque-Oliva E., Ky C., Ouedraogo A., Koukounari A., Gabrielli A.F., Bertrand S., Webster J.P., Fenwick A. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso. B World Health Organ 2008, 86:780-787.
52. van de Ven R., Scheffer G.L., Scheper R.J., de Gruijl T.D. The ABC of dendritic cell development and function. Trends Immunol. 2009, 30:421-429.
53. van der Werf M.J., de Vlas S.J., Brooker S., Looman C.W., Nagelkerke N.J., Habbema J.D., Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003, 86:125-139.
54. Vennervald B.J., Booth M., Butterworth A.E., Kariuki H.C., Kadzo H., Ireri E., Amaganga C., Kimani G., Kenty L., Mwatha J., Ouma J.H., Dunne D.W. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni. T. Roy. Soc. Trop. Med. H 2005, 99:150-160.
55. Xiao S.H., Catto B.A., Webster L.T. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J. Infect. Dis. 1985, 151:1130-1137.
56. Xu M., Molento M., Blackhall W., Ribeiro P., Beech R., Prichard R. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol. 1998, 91:327-335.
57. Zutz A., Gompf S., Schagger H., Tampe R. Mitochondrial ABC proteins in health and disease. Biochim. Biophys. Acta 2009, 1787:681-690.